

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
Form PTO-1449 (Modified)
(Use several sheets if necessary)

COMPLETE IF KNOWN

Application Number	10/567,470
Confirmation Number	4986
Filing Date	November 30, 2006
First Named Inventor	Iversen <i>et al.</i>
Group Art Unit	1645
Examiner Name	To be Assigned
Attorney Docket No.	50450-8055.US00

Sheet 1 of 6

U.S. PATENT DOCUMENTS

Examiner Initial	Cite No.	U.S. Patent or Application		Name of Patentee or Inventor of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		NUMBER	Kind Code (if known)			
	1.	US-2003/0166588	A1	Iversen <i>et al.</i>	09-04-2003	
	2.	US-2003/0171335	A1	Stein <i>et al.</i>	09-11-2003	
	3.	US-2003/0224353	A1	Stein <i>et al.</i>	12-04-2003	
	4.	US-2004/0072239	A1	Renaud <i>et al.</i>	04-15-2004	
	5.	US-2004/0259108	A1	Linnen <i>et al.</i>	12-23-2004	
	6.	US-2005/0176661	A1	Valliant <i>et al.</i>	08-11-2005	
	7.	US-2006/0063150	A1	Iversen <i>et al.</i>	03-23-2006	
	8.	US-2006/0149046	A1	Arar, Khalil	07-06-2006	
	9.	US-2006/0269911	A1	Iversen <i>et al.</i>	11-30-2006	
	10.	US-2007/0066556	A1	Stein <i>et al.</i>	03-22-2007	
	11.	US-2007/0129323	A1	Stein <i>et al.</i>	06-07-2007	
	12.	US-20070265214	A1	Stein <i>et al.</i>	11-15-2007	
	13.	US-5,142,047		Summerton <i>et al.</i>	08-25-1992	
	14.	US-5,495,006		Climie <i>et al.</i>	02-27-1996	
	15.	US-5,576,302		Cook <i>et al.</i> ,	11-19-1996	
	16.	US-5,580,767		Cowsert <i>et al.</i>	12-3-1996	
	17.	US-5,698,695		Summerton <i>et al.</i>	12-16-1997	
	18.	US-5,702,891		Kolberg <i>et al.</i>	12-30-1997	
	19.	US-5,734,039		Calabretta <i>et al.</i>	03-31-1998	
	20.	US-5,738,985		Miles <i>et al.</i>	04-14-1998	
	21.	US-5,955,318		Simons <i>et al.</i>	09-21-1999	
	22.	US-5,989,904		Das <i>et al.</i>	11-23-1999	
	23.	US-6,174,868		Anderson <i>et al.</i>	01-16-2001	
	24.	US-6,214,555	B1	Leushner <i>et al.</i>	04-10-2001	
	25.	US-6,258,570	B1	Glustein <i>et al.</i>	07-10-2001	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).

INFORMATION DISCLOSURE STATEMENT BY APPLICANT Form PTO-1449 (Modified) (Use several sheets if necessary)				COMPLETE IF KNOWN		
				Application Number	10/567,470	
				Confirmation Number	4986	
				Filing Date	November 30, 2006	
				First Named Inventor	Iversen <i>et al.</i>	
				Group Art Unit	1645	
Examiner Name	To be Assigned					
Attorney Docket No.	50450-8055.US00					
Sheet	2	of	6			

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.	U.S. Patent or Application		Name of Patentee or Inventor of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		NUMBER	Kind Code (if known)			
	26.	US-6,306,993		Rothbard et al.	10-23-2001	
	27.	US-6,365,577		Iversen	04-02-2002	
	28.	US-6,669,951	B2	Rothbard et al.	12-30-2003	
	29.	US-6,881,825	B1	Robbins et al.	04-19-2005	
	30.	US-7,115,374		Linnen et al.	10-03-2006	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.	Foreign Patent or Application			Name of Patentee or Applicant of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	NUMBER	Kind Code (if known)				
	31.	PCT	WO02/068637	A2	Ribozyme Pharmaceuticals, Inc.	09-06-2002		
	32.	PCT	WO03/033657	A2/A3	AVI Biopharma, Inc.	04-24-2003		
	33.	PCT	WO05/007805	A2/A3	AVI Biopharma, Inc.	01-27-2005		
	34.	PCT	WO05/013905	A2/A3	AVI Biopharma, Inc.	02-17-2005		

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to application(s).	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT Form PTO-1449 (Modified) (Use several sheets if necessary)				COMPLETE IF KNOWN	
				Application Number	10/567,470
				Confirmation Number	4986
				Filing Date	November 30, 2006
				First Named Inventor	Iversen <i>et al.</i>
				Group Art Unit	1645
Examiner Name	To be Assigned				
Sheet	3	of	6	Attorney Docket No.	50450-8055.US00

OTHER NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	T	
	35.	Bonham <i>et al.</i> , "An assessment of the antisense properties of RNase H-competent and steric-blocking oligomers", <i>Nucleic Acids Res.</i> , <u>23</u> (7):1197-203 (1995).		
	36.	Boudvillain <i>et al.</i> , "Transplatin-modified oligo(2'-O-methyl ribonucleotide)s: a new tool for selective modulation of gene expression", <i>Biochemistry</i> <u>36</u> (10):2925-31 (1997).		
	37.	Branch, Andrea D., "A good antisense molecule is hard to find", <i>Trends in Biochem. Sci.</i> , <u>23</u> :45-50 (1998).		
	38.	Brasey <i>et al.</i> , "The leader of human immunodeficiency virus type 1 genomic RNA harbors an internal ribosome entry segment that is active during the G2/M phase of the cell cycle", <i>Journal of Virology</i> , <u>77</u> (7):3939-3949 (2003).		
	39.	Clarke <i>et al.</i> , "Organization and expression of calicivirus genes", <i>J. Infect. Diseases</i> , <u>181</u> :S309-S316 (2000).		
	40.	Corey <i>et al.</i> , Morpgolino Antisense Oligonucleotides: Tools for Investigating Vertebrate Development, <i>Genome Biology</i> , <u>2</u> (5):1015.1-1015.3 (2001)		
	41.	Cross <i>et al.</i> , "Solution structure of an RNA x DNA hybrid duplex containing a 3'-thioformacetal linker and an RNA A-tract." <i>Biochemistry</i> , <u>36</u> (14):4096-107 (1997).		
	42.	Dagle <i>et al.</i> , "Targeted elimination of zygotic messages in <i>Xenopus laevis</i> embryos by modified oligonucleotides possessing terminal cationic linkages", <i>Nucleic Acids Res.</i> , <u>28</u> (10):2153-7 (2000).		
	43.	Deas, T.S., <i>et al.</i> , "Inhibition of flavivirus infections by antisense oligomers specifically suppressing viral translation and RNA replication", <i>Journal of Virology</i> , <u>79</u> (8):4599-4609, (2005).		
	44.	Ding, D., <i>et al.</i> , "An oligodeoxyribonucleotide N3'--> P5' phosphoramidate duplex forms an A-type helix in solution", <i>Nucleic Acids Res.</i> , <u>24</u> (2):354-60 (1996).		
	45.	Egholm <i>et al.</i> , "PNA hybridizes to complementary oligonucleotides obeying the Watson-Crick hydrogen-bonding rules." <i>Nature</i> , <u>365</u> (6446):566-8 (1993).		
	46.	Felgner <i>et al.</i> , "Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure", <i>PROC. NATL. ACAD. SCI. USA</i> , <u>84</u> (21):7413-7 (1987).		
	47.	Fischer, P.M., "Cellular uptake mechanisms and potential therapeutic utility of peptidic cell delivery vectors: progress 2001-2006" Published online 2006 in Wiley Interscience, www.interscience.wiley.com pages 1-41 (2006).		
	48.	Freier, S.M., in <i>Antisense Drug Technology: Principles, Strategies, and Applications</i> , Chapter 5, pp. 107-118 (2001).		

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT Form PTO-1449 (Modified) (Use several sheets if necessary)				COMPLETE IF KNOWN	
				Application Number	10/567,470
				Confirmation Number	4986
				Filing Date	November 30, 2006
				First Named Inventor	Iversen <i>et al.</i>
				Group Art Unit	1645
Examiner Name	To be Assigned				
Sheet	4	of	6	Attorney Docket No.	50450-8055.US00

OTHER NON PATENT LITERATURE DOCUMENTS			
Examine r Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	T
	49.	Gee <i>et al.</i> , "Assessment of high-affinity hybridization, RNase H cleavage, and covalent linkage in translation arrest by antisense oligonucleotides", <i>Antisense Nucleic Acid Drug Dev.</i> , <u>8</u> (2):103-11 (1998).	
	50.	Genbank Accession No. AF304460, Human coronavirus 229E, complete genome (July 2001).	
	51.	Green <i>et al.</i> , "Antisense oligonucleotides: an evolving technology for the modulation of gene expression in human disease", <i>J. Am. Coll. Surg.</i> , <u>191</u> :93-105 (2000).	
	52.	Hanacek <i>et al.</i> , "Antisense oligonucleotide inhibition of hepatitis C virus gene expression in transformed hepatocytes", <i>Journal of Virology</i> , <u>70</u> :5203-5212 (1996).	
	53.	Holland <i>et al.</i> , <i>Emerging Viruses</i> , Edited by Steven S. Morse, Oxford University Press, New York, Chapter 19, Replication Error, Quasispecies, Populations and Extreme Evolution Rates of RNA Viruses pages 203-218 (1993).	
	54.	Jaeger, J.A. <i>et al.</i> , "Improved predictions of secondary structures for RNA", <i>Proc. Natl. Acad. Sci. USA</i> , <u>86</u> :7706-7710 (1989).	
	55.	Johannes <i>et al.</i> , "Identification of eukaryotic mRNAs that are translated at reduced cap binding complex eIF4F concentrations using a cDNA microarray", <i>Proc. Natl. Acad. Sci. USA</i> , <u>96</u> (23):13118-13123 (1999).	
	56.	Jubin, R., <i>et al.</i> , "Hepatitis C virus internal ribosome entry site (IRES) stem loop III _d contains a phylogenetically conserved GGG triplet essential for translation and IRES folding", <i>Journal of Virology</i> , <u>74</u> (22):10430-10437 (2000).	
	57.	Liu <i>et al.</i> , "Structural and functional analysis of the 5' untranslated region of coxsackievirus B3 RNA: In vivo translational and infectivity studies of full-length mutants", <i>Virology</i> , <u>265</u> :206-217 (1999).	
	58.	Lopez De Quinto S. <i>et al.</i> , "Involvement of the aphthovirus RNA region located between the two functional AUGs in start codon selection", <i>Virology</i> , <u>255</u> (2):324-336 (1999).	
	59.	Markoff, L., "5'- and 3'-noncoding regions in flavivirus RNA", <i>Adv. Virus Res.</i> , <u>59</u> :177-228 (2003).	
	60.	McCaffrey <i>et al.</i> , "A potent and specific morpholino antisense inhibitor of hepatitis C translation in mice", <i>Hepatology</i> , <u>38</u> (2):503-508 (2003).	
	61.	Moulton <i>et al.</i> , Abstracts of Papers American Chemical Society National Meeting 226 (1-2): Biol 75 (Sept. 7-11, 2003).	
	62.	National Center for Biotechnology Information Report No. AF029248 from NCBI Genome Database (2000).	

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to application(s).	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT Form PTO-1449 (Modified) (Use several sheets if necessary)				COMPLETE IF KNOWN	
				Application Number	10/567,470
				Confirmation Number	4986
				Filing Date	November 30, 2006
				First Named Inventor	Iversen <i>et al.</i>
				Group Art Unit	1645
Examiner Name	To be Assigned				
Sheet	5	of	6	Attorney Docket No.	50450-8055.US00

OTHER NON PATENT LITERATURE DOCUMENTS			
Examine r Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	T
	63.	National Center for Biotechnology Information Report No. NC_002645 from NCBI Genome Database (2001).	
	64.	National Center for Biotechnology Information Report No. AY274119 from NCBI Genome Database (2003).	
	65.	Neuman et al. "Antisense morpholino-oligomers directed against the 5' end of the genome inhibit coronavirus proliferation and growth", <i>Journal of Virology</i> , 78(11):5891-5899 (2004).	
	66.	Orr <i>et al.</i> , <i>Current Opinion in Molecular Therapeutics, Current Drugs</i> , 2(3):325-331 (2000).	
	67.	Partridge et al., "A simple method for delivering morpholino antisense oligos into the cytoplasm of cells", <i>Antisense Nucleic Acid Drug Dev.</i> , 6(3):169-75 (1996).	
	68.	Raviprakash, K., et al., "Inhibition of dengue virus by novel, modified antisense oligonucleotides", <i>Journal of Virology</i> , 69(1):69-74, (1995).	
	69.	Rothbard <i>et al.</i> , "Arginine-rich molecular transporters for drug delivery: role of backbone spacing in cellular uptake", <i>J. Med. Chem.</i> , 45:3612-3618 (2002).	
	70.	Sankar e al., "Antisense oligonucleotide inhibition of encephalomyocarditis virus RNA translation", <i>European Journal of Biochemistry</i> , 184(1):39-45 (1989).	
	71.	Shengqi et al., "Synthesis of Antisense Phosphothioate Oligodeoxynucleotides of Dengue Fever Virus and Their Anti-Viral Activity", <i>Progress in Biochemistry and Biophysics</i> , 24:64-68 (English Translation) (1997).	√
	72.	Siprashvilli et al., "Gene transfer via reversible plasmid condensation with cysteine-flanked, internally spaced arginine-rich peptides", <i>Human Gene Therapy</i> , 14:1225-1233 (2003)	
	73.	Smith <i>et al.</i> , "Antisense treatment of caliciviridae: an emerging disease agent of animals and humans", <i>Current Opinion Molecular Therapeutcis</i> , 4(2):177-184 (2002).	
	74.	Smith, R.M. and Wu, G.Y., "Secondary structure and hybridization accessibility of the hepatitis C virus negative strand RNA 5'-terminus", <i>Journal of Viral Hepatitis</i> , 11:115-123 (2004).	
	75.	Stein et al., "A specificity comparison of four antisense types: morpholino, 2'-O-methyl RNA, DNA, and phosphorothioate DNA", <i>Antisense & Nucleic Acid Drug Development</i> , 7(3):151-7 (1997).	

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to application(s).	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT Form PTO-1449 (Modified) (Use several sheets if necessary)				COMPLETE IF KNOWN	
				Application Number	10/567,470
				Confirmation Number	4986
				Filing Date	November 30, 2006
				First Named Inventor	Iversen <i>et al.</i>
				Group Art Unit	1645
Examiner Name	To be Assigned				
Attorney Docket No.	50450-8055.US00				
Sheet	6	of	6		

OTHER NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	T
	76.	Stein <i>et al.</i> , "Inhibition of Vesivirus infections in mammalian tissue culture with antisense morpholino oligomers", <i>Antisense & Nucleic Acid Drug Development</i> , <u>11</u> (5):317-325 (2001).	
	77.	Thiel <i>et al.</i> , "Infectious RNA transcribed in vitro from a cDNA copy of the human coronavirus genome cloned in vaccinia virus", <i>Journal of General Virology</i> , <u>82</u> :1273-1281 (2001)	
	78.	Toulme <i>et al.</i> , Targeting RNA structures by antisense oligonucleotides." <i>Biochimie</i> , <u>78</u> (7): 663-73 (1996).	
	79.	Wages <i>et al.</i> , "Affinity purification of RNA: sequence-specific capture by nonionic morpholino probes", <i>Biotechniques</i> , <u>23</u> :1116-1121 (1997).	
	80.	Wang <i>et al.</i> , "Specific inhibition of coxsackievirus B3 translation and replication by phosphorothioate antisense oligodeoxynucleotides", <i>Antimicrobial Agents Chemotherapy</i> , <u>45</u> (4):1043-1052 (2001).	
	81.	Wei <i>et al.</i> , "Human immunodeficiency virus type-1 reverse transcription can be inhibited in vitro by oligonucleotides that target both natural and synthetic tRNA primers", <i>Nucleic Acids Res.</i> , <u>28</u> :3065-3074 (2000).	
	82.	Wilson et al., "Naturally occurring dicistronic cricket paralysis virus RNA is regulated by two internal ribosome entry sites", <i>Mol. Cell. Biol.</i> , <u>20</u> (14):4990-4999 (2000).	
	83.	Wu <i>et al.</i> , "Specific inhibition of hepatitis B viral gene expression in vitro by targeted antisense oligonucleotides", <i>J. Biol. Chem.</i> , <u>267</u> :12436-12439 (1992).	
	84.	Yuan et al., "A phosphorothioate antisense oligodeoxynucleotide specifically inhibits coxsackievirus B3 replication in cardiomyocytes and mouse hearts", <i>Labotratory Investigation</i> , <u>84</u> :703-714 (2004).	
	85.	Zhang <i>et al.</i> , "Antisense oligonucleotide inhibition of hepatitis C virus (HCV) gene expression in livers of mice infected with an HCV-vaccinia virus recombinant", <i>Antimicrobial Agents Chemotherapy</i> , <u>43</u> (2):347-353 (1999).	
	86.	Zuker, M., "Mfold web server for nucleic acid folding and hybridization prediction", <i>Nucleic Acids Res.</i> , <u>31</u> (13):3406-15 (2003).	

EXAMINER	/Jon Eric Angell/	DATE CONSIDERED	05/06/2010
*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to application(s).			